Tax-driven sale: Rocket Pharmaceuticals (RCKT) officer disposes 1,157 shares

Rhea-AI Filing Summary

Rocket Pharmaceuticals, Inc. officer John Militello reported an open-market sale of 1,157 shares of common stock at an average price of $3.338 per share. According to the filing, the shares were sold to cover tax withholding obligations from vesting restricted stock units, and he now holds 91,019 shares, including RSUs that convert one-for-one into common stock.

Insider Trade Summary

Net Seller: 1,157 shares ($3,862)

Net Sell 1 txn

Insider Militello John

Role See Remarks

Sold 1,157 shs ($4K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,157	$3.338	$4K

Holdings After Transaction: Common Stock — 91,019 shares (Direct)

Footnotes (1)

1. Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Militello John

(Last) (First) (Middle)

C/O ROCKET PHARMACEUTICALS, INC.

9 CEDARBROOK DRIVE

(Street)

CRANBURY NJ 08512

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ROCKET PHARMACEUTICALS, INC. [ RCKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	02/18/2026		S(2)		1,157	D	$3.338	91,019(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.

2. The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.

Remarks:

Vice President of Finance, Treasurer, Principal Accounting Officer

	/s/ Martin Wilson, as attorney-in-fact for John Militello	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Rocket Pharmaceuticals (RCKT) report for John Militello?

Rocket Pharmaceuticals reported that officer John Militello sold 1,157 shares of common stock. The transaction was an open-market sale primarily to satisfy tax withholding obligations triggered by the vesting of restricted stock units, rather than a discretionary sale of his investment position.

At what price were the Rocket Pharmaceuticals (RCKT) shares sold by John Militello?

John Militello sold 1,157 Rocket Pharmaceuticals shares at an average price of $3.338 per share. This price reflects the execution level for the open-market sale transaction used to cover tax withholding obligations related to recently vested restricted stock units granted by the company.

How many Rocket Pharmaceuticals (RCKT) shares does John Militello hold after the Form 4 transaction?

After the reported sale, John Militello beneficially owns 91,019 shares of Rocket Pharmaceuticals common stock. This total includes restricted stock units that convert into common shares on a one-for-one basis, as disclosed in the footnotes to the insider ownership and transaction report filing.

Why did John Militello sell Rocket Pharmaceuticals (RCKT) shares in this Form 4 filing?

The filing states Militello sold shares to pay tax withholding obligations tied to RSU vesting. When restricted stock units vest, taxes are due, and insiders often sell a portion of shares received to cover those obligations without using separate cash resources.

What type of transaction code appears in the Rocket Pharmaceuticals (RCKT) Form 4 for John Militello?

The transaction uses code “S,” indicating a sale in an open market or private transaction. Footnotes clarify the sale’s purpose was covering tax withholding on vesting restricted stock units, distinguishing it from a purely discretionary reduction of the insider’s equity exposure.